Infographic: The Future of Prostate Cancer Biomarkers Is Multiplexed

Combining urinary biomarkers improves clinical utility and provides a more robust evaluation

Oreoluwa Ogunyemi, MD

Oreoluwa Ogunyemi, MD, is a trained urologist and medical writer, who enjoys staying up to date on innovations in health care delivery.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Jul 07, 2021
|1 min read

Combining urinary biomarkers allows a complete evaluation of prostate cancer cells while minimizing the risk of missing a foci of cancer or a unique mutation that drives clinical outcomes.

Here, we explore commercially available multiplex urine biomarkers for detecting prostate cancer.

To learn about the future of prostate cancer biomarkers, download the FREE infographic courtesy of Clinical Lab Manager.